Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.127 EUR | -0.94% | +25.93% | -15.38% |
Business Summary
AsiDNA® is the first compound derived from platON®, a first-in-class inhibitor developed by the company. Based on a novel decoy and agonist mechanism acting upstream of multiple DDR pathways, it is highly differentiated from the tumor DNA damage response. Valerio Therapeutics is also developing OX425, a novel platON®-generated drug candidate optimized to be a next-generation PARP inhibitor, acting on both the DNA damage response and the activation of the immune response, without inducing resistance. OX425 is currently undergoing Investigational New Drug (IND)-enabling preclinical development.
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Oncology Products
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Rest of the World
100.0
%
| 4 | 100.0 % | 1 | 100.0 % | -64.48% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 21-05-31 |
Ashish Gulati
CTO | Chief Tech/Sci/R&D Officer | - | - |
Julien Miara
BRD | Director/Board Member | - | 20-09-16 |
Valérie Leroy
IRC | Investor Relations Contact | - | 16-11-30 |
Hui Ping Jiang
LAW | General Counsel | - | - |
Human Resources Officer | - | 15-02-09 | |
Philippe Maitre
PRN | Corporate Officer/Principal | 68 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jacques Mallet
BRD | Director/Board Member | 64 | 21-10-13 |
Khalil Barrage
BRD | Director/Board Member | 59 | - |
Director/Board Member | 61 | 11-06-28 | |
Julien Miara
BRD | Director/Board Member | - | 20-09-16 |
Bryan Giraudo
BRD | Director/Board Member | 48 | 21-11-22 |
Shefali Agarwal
CEO | Chief Executive Officer | 50 | 21-05-31 |
Robert L Coleman
BRD | Director/Board Member | - | 21-10-13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 154,364,273 | 114,123,888 ( 73.93 %) | 368,174 ( 0.2385 %) | 73.93 % |
Company contact information
Valerio Therapeutics SA
49, blvd. du Général Martial Valin
75015, Paris
+33 1 70 38 33 99
http://www.onxeo.comSector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+42.83% | 750B | |
+34.11% | 606B | |
-5.70% | 356B | |
+18.06% | 326B | |
+4.63% | 286B | |
+17.95% | 246B | |
+10.82% | 213B | |
-2.94% | 213B | |
+2.43% | 167B |
- Stock Market
- Equities
- ALVIO Stock
- C4X Stock
- Company Valerio Therapeutics